A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

Launched by HUYABIO INTERNATIONAL, LLC. · Aug 2, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called HBI-2438 in patients with advanced solid tumors that have a specific genetic change known as the KRAS G12C mutation. The main goal is to find out the highest dose of HBI-2438 that can be safely given and to understand how the drug behaves in the body. This trial is for adults aged 18 and older who have already tried or cannot benefit from standard cancer treatments. Participants should have measurable cancer that can be tracked and must be in good enough health to take oral medications.

If eligible, participants can expect to take HBI-2438 and undergo regular check-ups to monitor their health and the effects of the medication. The trial is currently recruiting and aims to help improve treatment options for patients with specific types of cancers, including lung and colorectal cancers. It’s important to note that individuals with certain health conditions or other cancers, as well as those who are pregnant or nursing, may not qualify for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Key Inclusion Criteria:
• • Male or female at least 18 years of age at the time of signing the ICF prior to initiation of any study specific activities/procedures
• • Advanced malignant solid tumors with KRAS G12C mutation- as determined by genetic testing
• • Must have failed or refused standard of care therapy, are not eligible for standard of care therapy, or cannot benefit from standard of care therapy, in the opinion of the Investigator
• • At least 1 measurable target lesion that meets the definition of RECIST v1.1
• • ECOG Performance Status of 0 or 1
• • Demonstrate adequate organ function
• • Expected survival time \> 3 months in the opinion of the investigator
• • Must be able to swallow oral medications and must not have gastrointestinal abnormalities that significantly affect drug absorption
• Exclusion Criteria:
• Key Exclusion Criteria:
• • History of another concurrent malignancy within 3 years prior to study entry, unless the malignancy was treated with curative intent and the likelihood of relapse is \<5% in 2 years Note: Subjects with a history of squamous or basal cell carcinoma of the skin or carcinoma in the situ of the cervix may be enrolled
• • Untreated or symptomatic central nervous system (CNS) metastases Note: Subjects with asymptomatic treated CNS metastases are eligible provided they have been clinically stable and not requiring steroids for at least 4 weeks
• • Clinically significant cardiovascular disease, including stroke or myocardial infarction within 6 months prior to first dose of HBI-2438; or the presence of unstable angina or congestive heart failure of New York Heart Association Grade 2 or higher
• • Any unresolved Grade 2 or greater toxicity from previous anti-cancer therapy, except alopecia, within 4 weeks of first study treatment administration
• • Active autoimmune diseases or history of autoimmune diseases that may relapse
• • Pregnant or nursing
• • Prior treatment with any KRAS G12C inhibitors
• • Any condition that required systemic treatment with either corticosteroids (\>10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤14 days before the first study treatment administration
• • Treatment with other investigational drugs/devices within 4 weeks prior to first study treatment administration